

Resource Summary Report

Generated by [RRID](#) on Aug 7, 2026

CyTekBio: Aurora Spectral Analyzer

RRID:SCR_019826

Type: Tool

Proper Citation

CyTekBio: Aurora Spectral Analyzer (RRID:SCR_019826)

Resource Information

URL: <https://cytekbio.com/pages/aurora>

Proper Citation: CyTekBio: Aurora Spectral Analyzer (RRID:SCR_019826)

Description: Analyzer with up to five lasers, three scattering channels, and 64 fluorescence channels, the Aurora suits every laboratory's needs, from to high complexity applications. A paradigm shifting optical design provides unprecedented flexibility, enabling the use of a wide array of new fluorochrome combinations without reconfiguring your system for each application. The state-of-the-art optics and low-noise electronics provide excellent sensitivity and resolution. Flat-top beam profiles, combined with a ly designed fluidics system, translate to outstanding performance at high sample flow rates.

Synonyms: Cytex Aurora

Resource Type: instrument resource

Keywords: Cytex, Spectral Analyzer, Instrument, Equipment, USEDit

Availability: Commercially available

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_019826.pdf

Resource Name: CyTekBio: Aurora Spectral Analyzer

Resource ID: SCR_019826

Alternate IDs: Model_Number_Aurora

Record Creation Time: 20220129T080347+0000

Record Last Update: 20260801T190644+0000

Ratings and Alerts

No rating or validation information has been found for CyTekBio: Aurora Spectral Analyzer.

No alerts have been found for CyTekBio: Aurora Spectral Analyzer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 54 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Hinterleitner C, et al. (2026) Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer. bioRxiv : the preprint server for biology.

Wei X, et al. (2026) Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade. Cancer discovery, 16(6), 1152.

Martín A, et al. (2026) Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. Cancer research.

Nelson MC, et al. (2026) MicroRNA-146a Protects against Hepatocellular Carcinoma through Suppression of CCL5. Cancer research communications, 6(2), 359.

Stahr N, et al. (2026) STAT4-dependent regulation of neuroinflammation in atherosclerosis. Physiological reports, 14(7), e70856.

Stahr N, et al. (2026) STAT4-dependent regulation of neuroinflammation in atherosclerosis. bioRxiv : the preprint server for biology.

Yatim A, et al. (2026) Human LFA-1 governs T cell immune surveillance of the skin. Science immunology, 11(116), eadz8360.

Drouillard D, et al. (2026) Mutant KRAS promotes NF- κ B driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma. bioRxiv : the preprint server for biology.

Fischer TD, et al. (2026) Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic γ PD-1 Activate Tumor-Specific CD8⁺ T Cells. Cancer research communications, 6(5), 1006.

Eme-Solan E, et al. (2026) Remodeling of skull bone channels regulates immune infiltration into the meninges during neuroinflammation. Immunity, 59(1), 116.

Belanger K, et al. (2026) Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. Cancer research,

86(14), 3604.

Suzuki K, et al. (2026) Targeting the $\alpha 5 \beta 1$ Integrin Modifies the TGF β -Rich Tumor Microenvironment of Pancreatic Cancer. *Cancer research*, 86(15), 3801.

Nathan N, et al. (2026) Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells. *Immunity*, 59(6), 1743.

Anderko RR, et al. (2026) Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(3), 596.

Ye J, et al. (2026) Baseline Tumor Features and Systemic Immune Dynamics Underlying Efficacy in MSS Metastatic Colorectal Cancer Treated with Regorafenib, Ipilimumab, and Nivolumab. *Cancer immunology research*, 14(4), 585.

Magno JC, et al. (2026) Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. *Cancer research*, 86(11), 2688.

Turnquist A, et al. (2026) PI3K γ inhibition alters CD8 T cell differentiation and reprograms the tumor microenvironment following adoptive immunotherapy. *Journal of immunology (Baltimore, Md. : 1950)*, 215(5).

Braams M, et al. (2026) ABO: A 3D stroma-supported culture platform enabling full human B-lymphopoiesis for disease modeling and gene therapy development. *Cell reports. Medicine*, 7(7), 102879.

Tang E, et al. (2026) Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. *Cancer immunology research*, 14(8), 1292.

Mesquita M, et al. (2026) Hypomorphic biliverdin reductase a mutations define bilirubin anti-malarial threshold. *iScience*, 29(6), 115958.